Inhibitory Effect Analysis of Pioglitazone on Inflammation Factors in Patients with Bladder Cancer
10.3969/j.issn.1671-7414.2015.02.014
- VernacularTitle:吡格列酮对膀胱癌患者机体炎症因子抑制作用的分析
- Author:
Yi LIU
;
Xuan ZHANG
;
Huyi LI
;
Xuliang ZHANG
;
Weihe QUAN
;
Zhenqi WU
- Publication Type:Journal Article
- Keywords:
pioglitazone;
bladder cancer;
inflammation factor
- From:
Journal of Modern Laboratory Medicine
2015;(2):46-48
- CountryChina
- Language:Chinese
-
Abstract:
Objecitve To study the inhibitory effect of pioglitazone on inflammation factors in patients with bladder cancer. Methods A total of 100 consecutives diagnosed as bladder cancer from Februray 2013 to Februray 2014 were individed ran-domly into experiment and control groups and each of 50 cases.All patients received the appropriate operation or chemother-apeutic regimens,and the patients in experiment group received pioglitazone (15 mg/d×12 weeks)at the same time.Then to compare expression differences of high-sensitive C reactive protein (hs-CRP),tumor necrosis factor alpha (TNF-alpha),in-terleukin (IL-6)and HOMA-IR,MCP-1,MIP-1 levels.Results The levels of hs-CRP,TNF-αand IL-6 in the two groups af-ter treatment were all lower (P <0.05),and in experiment groups they were significantly lower than control group (P <0.05).The levels of HOMA-IR,MCP-1 and MIP-1 in the two groups after treatment were all lower (P <0.05),and in ex-periment groups they were significantly lower than control group(P <0.05).The complication rate in the two groups were no statistical difference (P >0.05).Conclusion Pioglitazone could improve clinical effect and prognosis by lowing inflam-mation factors including hs-CRP,TNF-α,IL-6,HOMA-IR,MCP-1 and MIP-1 in patients with bladder cancer.
